New phase 1 entrants include Claudin18.2-targeting ADCs from Astra and Bolt.
ApexOnco Front Page
Recent articles
Three off-the-shelf mRNA therapies join intismeran autogene.
The Artistry-7 Keytruda combo trial fails, spurring discontinuation in ovarian cancer.
The company is stepping back in second-line breast cancer.
First-in-human study listings include EOS-215 and RO7673396.
The company’s matching strategy for CB-010 will soon be put to the test.
Vobra-duo is discontinued at long last.
After Astra's EsoBiotec takeover the battle for uniqueness begins.
